Advocacy intelligence hub — real-time data for patient organizations
RETEVMO: FDA approved
treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy; and treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
RETEVMO
Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
Browse all Non-functioning neuroendocrine tumor of pancreas news →
Alberto Larghi, PhD, MD
Fondazione Policlinico Universitario Agostino Gemelli
📍 ROME, ITALY
Jennifer A Chan
Alliance for Clinical Trials in Oncology
Nageshwara V Dasari, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Daniel M Halperin, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Tianhong Li, MD, MD,Ph.D
University of California, Davis
📍 SACRAMENTO, CA
Olov Norlén, MD, PhD
Uppsala University Hospital
View all Non-functioning neuroendocrine tumor of pancreas specialists →